Saccharin

Saccharin

SCHEMBL4624412

O=C1NS(=O)(=O)c2ccccc21.[NaH].[NaH]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 7/20 0.96
CA9 Q16790 7/20 0.96
CA2 P00918 5/20 0.96
CA1 P00915 4/20 0.96
CA7 P43166 3/20 0.96
KDM4E B2RXH2 3/20 0.96
CA4 P22748 2/20 0.96
USP2 O75604 1/20 0.96
LMNA P02545 1/20 0.96
BCHE P06276 1/20 0.96
CA6 P23280 1/20 0.96
CA5A P35218 1/20 0.96
KMT2A Q03164 1/20 0.96
CA14 Q9ULX7 1/20 0.96
CA5B Q9Y2D0 1/20 0.96
ALDH1A1 P00352 3/20 0.58
RET P07949 2/20 0.53
GRK5 P34947 2/20 0.53
TYRO3 Q06418 2/20 0.53
DYRK1B Q9Y463 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Saccharin SCHEMBL3373 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL10627242 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL3374 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL8802065 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL10899217 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL514398 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL11399526 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL9463482 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL9463164 1.00 CA12 (0.96) CA12CA9CA2CA1CA7
Saccharin SCHEMBL8214948 1.00 CA12 (0.96) CA12CA9CA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105769924-A Propolis oral antifungal cream and preparing method thereof 湖北艾莱福生物科技有限公司 2016-07-20 CN claimed
CN-220213925-U A concentrated cauldron for saccharin sodium draws 河北允升生物科技有限公司 2023-12-22 CN disclosed
EP-3413716-A1 SYNTHESIS AND APPLICATION OF AN ANTIMICROBIAL ACTIVE Salicylates & Chemicals Pvt ltd (IN) 2018-12-19 EP disclosed
EP-3248594-A1 TABLET FOR MULTIPLE ORAL APPLICATIONS ratiopharm GmbH (DE) 2017-11-29 EP disclosed
WO-2017137818-A1 SYNTHESIS AND APPLICATION OF AN ANTIMICROBIAL ACTIVE SALICYLATES & CHEMICALS (IN) 2017-08-17 WO disclosed
EP-3096710-A1 DENTAL TREATMENT CAPSULE, FORMULATION AND DEVICE Smartjet Technologies Ltd. (IL) 2016-11-30 EP disclosed
WO-2015111051-A1 DENTAL TREATMENT CAPSULE, FORMULATION AND DEVICE SMARTJET TECHNOLOGIES LTD (IL) 2015-07-30 WO disclosed
EP-1904185-A2 ORAL COOMPOSITIONS HAVING CATIONIC ACTIVE INGREDIENTS Colgate-Palmolive Company (US) 2008-04-02 EP disclosed
WO-2007011552-A2 ORAL COOMPOSITIONS HAVING CATIONIC ACTIVE INGREDIENTS COLGATE-PALMOLIVE COMPANY (US) 2007-01-25 WO disclosed
US-20070014740-A1 Oral compositions having cationic active ingredients COLGATE-PALMOLIVE COMPANY 2007-01-18 US disclosed
WO-2006112533-A1 WATER-CONTAINING GEL FORM AND PRODUCTION METHOD THEREOF SHOWA DENKO K.K. (JP) 2006-10-26 WO disclosed
CN-1830442-A Compound formula dextro methaphen oral disintegration tablet and its preparation method SHENZHEN PHARMACEUTICAL FACTOR (CN) 2006-09-13 CN disclosed
EP-0670160-B1 Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation GERGELY GERHARD (AT) 1999-07-14 EP disclosed
WO-1995023594-A1 GRANULAR PRODUCT OR TABLET CONTAINING AN EFFERVESCENT SYSTEM AND AN ACTIVE PHARMACEUTICAL SUBSTANCE, AS WELL AS A METHOD FOR ITS PREPARATION GERGELY GERHARD (AT) 1995-09-08 WO disclosed
EP-0670160-A1 Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation Gergely, Gerhard, Dr. (AT) 1995-09-06 EP disclosed
US-4775523-A Dentifrice sachet COLGATE-PALMOLIVE COMPANY (US) 1988-10-04 US disclosed
US-4361580-A TASTELESS ANTIINFLAMMATORY AGENT THE UPJOHN MANUFACTURING COMPANY (US) 1982-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014740-A1 Oral compositions having cationic active ingredients EXOSC9, TAS2R7, TAS2R39 CA12 3647/4885CA9 2152/4885CA2 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.